Open access · CC-BY
via OpenAlex
Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes
Peter C. Reifsnyder, Kevin Flurkey, Austen G. Te, David E. Harrison
Aging · 2016 · ▲ 57 citations
Abstract
Numerous studies suggest that mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) treatment promotes insulin resistance, implying that rapamycin could have negative effects on patients with, or at risk for, type 2 diabetes (T2D). New evidence, however, indicates that rapamycin treatment produces some benefits to energy metabolism, even in the context of T2D. Here, we survey 5 mouse models of T2D (KK, KK-Ay, NONcNZO10, BKS-db/db, TALLYHO) to quantify effects of rapamycin on well-recognized markers of glucose homeostasis within a wide range of T2D environments. Interestingly, dietary rapamycin treatment did not exacerbate impaired glucose or insulin tolerance, or elevate circulating lipids as T2D progressed. In fact, rapamycin increased insulin sensitivity and reduced weight gain in 3 models, and decreased hyperinsulinemia in 2 models. A key covariate of this genetically-based, differential response was pancreatic insulin content (PIC): Models with low PIC exhibited more beneficial effects than models with high PIC. However, a minimal PIC threshold may exist, below which hypoinsulinemic hyperglycemia develops, as it did in TALLYHO. Our results, along with other studies, indicate that beneficial or detrimental metabolic effects of rapamycin treatment, in a diabetic or pre-diabetic context, are driven by the interaction of rapamycin with the individual model’s pancreatic physiology.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.18632/aging.101117
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Reifsnyder, P.C., Flurkey, K., Te, A.G., & Harrison, D.E. (2016). Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes. <em>Aging</em>. https://doi.org/10.18632/aging.101117
Vancouver
Reifsnyder PC, Flurkey K, Te AG, Harrison DE. Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes. Aging. 2016. doi:10.18632/aging.101117.
BibTeX
@article{peter2016Rapamy,
title = {Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes},
author = {Peter C. Reifsnyder and Kevin Flurkey and Austen G. Te and David E. Harrison},
journal = {Aging},
year = {2016},
doi = {10.18632/aging.101117},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Molecular Medicine 2011
Open access · CC-BY
Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity
IOSR Journal of Pharmacy (IOSRPHR) 2014
Open access · OA
Rapamycin reduces Drosophila longevity under low nutrition
Nutrients 2022
Open access · CC-BY
Intermittent Fasting: Potential Bridge of Obesity and Diabetes to Health?
GeroScience 2022
Open access · CC-BY
Rapamycin not dietary restriction improves resilience against pathogens: a meta-analysis
Aging 2014
Open access · CC-BY
Rapamycin-induced metabolic defects are reversible in both lean and obese mice
Nutrients 2019
Open access · CC-BY